VAR2 will be represented by its COO, Andreas Linderoth Norlin, at this year's BIO International Convention taking place in Boston 4th to 7th June. We look forward to a great program and many exciting meetings with old and new partners in the biopharma business. See you there!
...
VAR2 Pharmaceuticals founder and member of the Board of Directors, Prof. Poul Sorensen, will give a talk with the title “Probing the surface proteome for immunotherapy targets in high-risk pediatric cancers” on Saturady April 14th at the AACR meeting in Chicago, IL. The presentation will highlight s......
New significant data about chondroitin sulphate – the target for the VAR2 protein – in prostate cancer, will be presented on April 18th, at this year's AACR meeting in Chicago, IL. The work is presented in a poster entitled “Expression and regulation of chondroitin sulfate in prostate cancer” and is......
Today the Innovation Fund Denmark (innovationsFonden) granted 1 million DKK over 3 years to VAR2 Pharmaceuticals and Copenhagen University to fund an Industry PhD student in the project “Cancer immunotherapy based on a malaria protein”. We are very happy for the grant and look forward to work with t......